Clinical Trial: NCT06711900
A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 3| Lead Sponsor: | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
| Information Provided By: | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
| Last Update Posted: | 2026-07-08 |
Study Overview
Brief Summary
The study aims to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab versus chemotherapy in combination with pembrolizumab in the first-line treatment of patients with locally advanced or metastatic non-squamous NSCLC with PD-L1 negative.
Official Title
A Randomized, Open-Label, Multicenter Phase 3 Clinical Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Conditions
Non-Small Cell Lung Cancer
Intervention / Treatment
- Drug: SKB264
- Drug: Pembrolizumab
- Drug: pemetrexed
- Drug: carboplatin or cisplatin
Other Study ID Numbers
- SKB264-Ⅲ-14
Start Date (Actual)
2024-10-30
Primary Completion Date (Estimated)
2026-12
Study Completion Date (Estimated)
2028-12
Enrollment (Estimated)
432
Study Type
Interventional
Phase
Phase 3
| Lead Sponsor: | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
| Information Provided By: | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
| Last Update Posted: | 2026-07-08 |
Study Overview
Brief Summary
The study aims to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab versus chemotherapy in combination with pembrolizumab in the first-line treatment of patients with locally advanced or metastatic non-squamous NSCLC with PD-L1 negative.
Official Title
A Randomized, Open-Label, Multicenter Phase 3 Clinical Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Conditions
Non-Small Cell Lung Cancer
Intervention / Treatment
- Drug: SKB264
- Drug: Pembrolizumab
- Drug: pemetrexed
- Drug: carboplatin or cisplatin
Other Study ID Numbers
- SKB264-Ⅲ-14
Start Date (Actual)
2024-10-30
Primary Completion Date (Estimated)
2026-12
Study Completion Date (Estimated)
2028-12
Enrollment (Estimated)
432
Study Type
Interventional
Phase
Phase 3